DiscoverCME in Minutes: Education in Cardiology & PulmonologyMark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses
Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Update: 2025-12-01
Share

Description

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Answers in CME